Press releases about defined endpoints of phase 3 trials are the ones that move the stock price the most, next to mergers. Probably across all companies, not just pharma. The SEC would come calling if they were lies.
That was my basic understanding as well. The claims in these kinds of press releases would be particularly scrutinized by, e.g. the SEC, FDA, etc..
I hadn’t known until I met someone that did it, but many (basically all?) companies have investor relations personnel or consultants. I know that some of those IR people also specialize in pharmaceutical or biomedical companies. They would definitely be involved in writing these kinds of press releases too.
Press releases about defined endpoints of phase 3 trials are the ones that move the stock price the most, next to mergers. Probably across all companies, not just pharma. The SEC would come calling if they were lies.
That was my basic understanding as well. The claims in these kinds of press releases would be particularly scrutinized by, e.g. the SEC, FDA, etc..
I hadn’t known until I met someone that did it, but many (basically all?) companies have investor relations personnel or consultants. I know that some of those IR people also specialize in pharmaceutical or biomedical companies. They would definitely be involved in writing these kinds of press releases too.